NRX
Nurexone Biologi
Stock
Stock
ISIN: CA67059R1091
Ticker: NRX
CA67059R1091
NRX
Price
Price
CHART BY
Frequently asked questions
What is Nurexone Biologi's market capitalization?
The market capitalization of Nurexone Biologi is $37.99M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Nurexone Biologi?
Nurexone Biologi's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.111. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Nurexone Biologi's stock?
Currently, 1 analysts cover Nurexone Biologi's stock, with a consensus target price of $2.214. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Nurexone Biologi?
Nurexone Biologi's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$6.76M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Nurexone Biologi?
Nurexone Biologi has a free cash flow of -$7.59M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Nurexone Biologi's shares?
The free float of Nurexone Biologi is 54.31M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $37.99M
- EPS (TTM)
- -$0.111
- Free Float
- 54.31M
- EBITDA (TTM)
- -$6.76M
- Free Cashflow (TTM)
- -$7.59M
Pricing
- 1D span
- $0.449$0.487
- 52W span
- $0.335$0.634
Analyst Ratings
The price target is $2.214 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. It focuses on the treatment of spinal cord injury, traumatic brain injury, and other brain and neurological indications. The company was founded on June 27, 2011 and is headquartered in Bnei-Brak, Israel.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CA67059R1091
- Primary Ticker
- NRX
Knockouts
LSX Data · Fundamentals & EOD data from FactSet